Streetbeat News

Stock Prices

CGEM

Cullinan Therapeutics Inc (NASDAQ:CGEM), previously known as Cullinan Oncology Inc, is shifting its focus from oncology to autoimmune diseases, specifically targeting systemic lupus erythematosus (SLE) with its CLN-978 treatment. The company plans to submit an investigational new drug application for CLN-978 in SLE by Q3 2024 and has raised $280 million through a private placement to fund operations into 2028. William Blair initiated coverage on Cullinan with an Outperform rating and a $35-per-share fair value, highlighting the company's diversified pipeline and strategic flexibility.

Portfolio Pulse from Vandana Singh

April 16, 2024 | 5:32 pm

DE

Over the past 5 years, Deere (NYSE:DE) has produced an average annual return of 18.41%, outperforming the market by 6.72% on an annualized basis. A $100 investment in DE 5 years ago would now be worth $232.81. Deere's market capitalization currently stands at $109.62 billion.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 5:30 pm

OMI

Owens & Minor (NYSE:OMI) has significantly outperformed the market, with an annualized return of 48.79% over the past 5 years, growing a $1000 investment to $7,292.65. The company now has a market capitalization of $1.91 billion.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 5:30 pm

FE

FirstEnergy (NYSE:FE) has seen a 5.18% increase in its short percent of float since the last report, with 11.63 million shares sold short, representing 2.64% of available shares. This indicates a bearish market sentiment, although it doesn't necessarily predict a near-term price drop. FirstEnergy's short interest is higher than its peer group average of 2.44%.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 5:30 pm

AMAT

Applied Materials, Inc. (NYSE:AMAT) has seen a decrease in short interest, now at 1.5% of float, lower than the peer group average of 7.13%. This reduction from 12.45 million shares suggests a more bullish sentiment among investors. The coverage time for short positions based on current trading volume is approximately 2.87 days.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 5:30 pm

ORCL

Oracle's (NYSE:ORCL) short interest has decreased by 22.86%, now standing at 12.96 million shares or 0.81% of its float. This reduction in short interest, which now takes traders approximately 1.38 days to cover, could indicate a more bullish sentiment towards ORCL compared to its peers, where the average short interest as a percentage of float is 4.47%.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 5:30 pm

BAC

DIA

MS

QQQ

SPY

TLT

TSLA

Geopolitical tensions and economic forecasts shape market trends, with mixed performances in U.S. stocks and sectors. The IMF's optimistic U.S. growth projection contrasts with potential Middle East escalations. Treasury yields rise, impacting bond ETFs like TLT. Gold nears record highs, while Bitcoin drops. Key stocks and ETFs like SPY, DIA, QQQ, and sector-specific funds XLV and XLE show varied performances. Companies like TSLA, BAC, MS, and others react to news and earnings, influencing their stock prices.

Portfolio Pulse from Piero Cingari

April 16, 2024 | 5:28 pm

PALI

Maxim Group analyst Naz Rahman has maintained a Buy rating on Palisade Bio (NASDAQ:PALI) and adjusted the price target to $22.5, following a 1:15 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 5:27 pm

GEV

Goldman Sachs analyst Joe Ritchie initiated coverage on GE Vernova Inc (NYSE:GEV) with a Buy rating and a price target of $154, highlighting the company's unique position in electrification and decarbonization. Ritchie emphasized GEV's significant contribution to global electricity supply, its turnaround in the Power business, and the under-estimated growth potential in Wind and Electrification. Despite recent progress, GEV's shares dropped 1.36% to $129.96.

Portfolio Pulse from Shivani Kumaresan

April 16, 2024 | 5:27 pm

DKNG

DraftKings shares surged following a positive initiation by Goldman Sachs, which gave the stock a buy rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 5:25 pm